Showing results (51-60 of 225) with videos related to

Sort By:
Pageof 23
Cancer Biology & Therapy|July 25, 2012
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAmelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, et al.
Pharmacogenomics and Personalized Medicine|April 10, 2014
Targeted treatments in advanced renal cell carcinoma: focus on axitinibElena Verzoni, Paolo Grassi, Isabella Testa, et al.
Anticancer Research|August 5, 2006
Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter studyAntonio Frega, Deborah French, Sebastiano Pace, et al.
Cancers|October 30, 2019
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old StoryGeny Piro, Carmine Carbone, Luisa Carbognin, et al.
Cancer Treatment Reviews|March 11, 2023
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenarioChiara Ciccarese, Alessandro Strusi, Daniela Arduini, et al.
Cancers|February 10, 2024
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?Martina Panebianco, Chiara Ciccarese, Alessandro Strusi, et al.
Plos One|October 1, 2014
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studiesRoberto Iacovelli, Filippo Pietrantonio, Alessio Farcomeni, et al.
Expert Review of Anticancer Therapy|June 16, 2024
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysisChiara Ciccarese, Annunziato Anghelone, Alessio Stefani, et al.
Critical Reviews in Oncology/Hematology|January 29, 2016
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agentsRoberto Iacovelli, Elena Verri, Maria Cossu Rocca, et al.
Seminars in Oncology|January 23, 2019
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysisChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.
Pageof 23